Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person’s own immune system to fight cancer. It has several advantages over standard cancer therapies, including fewer side effects and an overall better tolerability. It tends to be most effective in patients who have smaller, localized tumors that have not spread to distant sites.
“This clinical trial is to assess ID-G305 and its ability to activate the immune system in patients with advanced stage melanoma, sarcoma, lung, ovarian, or breast cancer,” said Amit Mahipal, M.D., M.P.H., medical director of Moffitt’s Clinical Research Unit. “Our first patient in this trial is a metastatic sarcoma patient who has undergone two previous surgeries and one chemotherapy regimen.”
ID-G305 is a cancer vaccine that is made up of two parts, a protein called NY-ESO-1 that is found in many different types of cancer, and an agent called GLAASTM developed by Immune Design. GLAASTM activates a type of cell called a dendritic cell that normally searches for pathogens in the body and helps the immune system fight against the infection. Following vaccination, the GLAASTM-activated dendritic cells recognize NY-ESO-1 as a foreign protein and cause the body to produce an immune response. Since NY-ESO-1 is found on tumors, the immune system begins targeting the cancer cells.
“Only 10 to 15 percent of all tumors have NY-ESO-1 protein expression. Therefore, patients for this trial need to be to be screened for NY-ESO-1. The vaccine will likely not work for patients with tumors that do not have detectable levels of the protein,” said Mahipal.
Each component of ID-G305 has been used previously as a single-agent in clinical trials and was well tolerated by patients. This trial will determine the ideal concentration of each agent to use in combination. Common side effects expected include pain, redness, and inflammation at the site of injection.
This is an exciting time for the development of new immunotherapies to fight cancer. Several immunotherapy agents have recently been approved by the Food and Drug Administration, including interleukin-2 for melanoma and renal cell carcinoma, Provenge for prostate cancer and ipilimumab for melanoma.
“New immune therapies are emerging,” explained Mahipal. “If we can have immune therapy actually work it would be great for the patient and reduce side effects associated with traditional chemotherapies.”
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Single-Cell Spatial Analysis for Immunotherapy Response Prediction in Early TNBC Shows Promiseon December 7, 2021 at 6:12 am
Imaging mass cytometry at the single-cell level showed potential as an immunotherapy response prediction tool in early triple-negative breast cancer.
- ATP Launches Adendra Therapeutics, a New Kind of Immunotherapy Company Deploying Novel Insights into Dendritic Cell Biology, with $53M Series Aon December 7, 2021 at 12:30 am
ATP (Apple Tree Partners), a leader in life sciences venture capital, today announced the launch of Adendra Therapeutics Ltd. ("Adendra"), a company that will discover and develop treatments for ...
- Dr. Qin on Treatment Considerations for Immunotherapy in NSCLCon December 6, 2021 at 2:35 pm
Angel Qin, MD, discusses treatment considerations for immunotherapy in patients with newly diagnosed non–small cell lung cancer.
- Combination Immunotherapy Helps Patients With Kidney Cancer Live Longer and ‘Get Back to Their Regular Lives’on December 6, 2021 at 12:00 pm
Survival with Opdivo and Yervoy was more than twice as long when compared with Sutent alone in patients with kidney cancer.
- New immunotherapy for leukemia discoveredon December 6, 2021 at 10:36 am
Researchers at Karolinska Institutet, University of Oslo and Oslo University Hospital have developed a new kind of immunotherapy for leukemia. The results of a study published in Nature Biotechnology ...
- 'Highest Survival' With Combo Immunotherapy in Advanced Melanomaon December 6, 2021 at 7:41 am
Half of patients treated with combination immunotherapy were still alive after 6.5 years, representing the longest overall survival observed in a phase 3 trial of advanced melanoma.
- Glioblastomas, the aggressive brain tumors, might benefit from immunotherapy in some patients, Northwestern research suggestson December 3, 2021 at 7:41 am
Immunotherapy has helped other cancer patients, but so far hasn't shown promise for glioblastomas. A Northwestern study offers hope.
- Activating immune cells for cancer nano-immunotherapyon December 3, 2021 at 6:09 am
With nanotechnology we can understand, mimic, and modulate our immune system. For her Ph.D. research, Annelies Wauters studied how tiny nanocarriers can be used to control the immune system, and ...
- Does cancer immunotherapy work differently in men vs. women?on December 2, 2021 at 8:01 am
A class of cancer immunotherapy called checkpoint inhibitors has revolutionized cancer treatment. It's a new way to attack the disease by unleashing the immune system. However, not every patient ...
- Immunotherapy Shows Promise for Difficult-to-Treat HRP Ovarian Canceron December 1, 2021 at 2:01 pm
A novel immunotherapy provided durable disease control in homologous repair proficient (HRP) ovarian cancer, subgroup data from a small randomized trial showed. After 3 years of follow-up, median ...
via Bing News